Suppr超能文献

单独使用或与流感疫苗联合使用的肺炎球菌疫苗在透析患者中的有效性和安全性:一项系统评价和荟萃分析。

Effectiveness and safety of pneumococcal vaccines used alone or combined with influenza vaccination in dialysis patients: A systematic review and meta-analysis.

作者信息

Mo Yenan, Zeng Jiahao, Xiao Cuixia, Zhang La, Wang Lixin, Lu Fuhua, Johnson David W, Stålsby Lundborg Cecilia, Nitsch Dorothea, Liu Xusheng, Su Guobin

机构信息

Department of Nephrology, Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou city, Guangdong Province, China; The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou city, Guangdong Province, China.

The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou city, Guangdong Province, China.

出版信息

Vaccine. 2020 Nov 3;38(47):7422-7432. doi: 10.1016/j.vaccine.2020.09.080. Epub 2020 Oct 12.

Abstract

BACKGROUND

A lower conversion vaccination rate and a more rapid decline in antibody titers over time in dialysis patients raise concerns about the effectiveness of pneumococcal vaccination (PV) in this population, which has not been systematically reviewed.

METHODS

We searched PubMed, Cochrane Library, Embase and three Chinese databases from inception until February 29th, 2020 for interventional, cohort and case-control studies evaluating PV alone or combined with influenza vaccination (IV) on outcomes (all-cause mortality, pneumonia, cardiovascular events, antibody response and safety). Independent reviewers completed citation screening, data extraction, risk assessment, meta-analysis, and GRADE rating of the quality of evidence.

RESULTS

Five cohort studies and one quasirandomized control trial enrolling 394,299 dialysis patients with high to moderate quality were included. Compared with unvaccinated individuals, those receiving PV had lower risk of all-cause mortality [Adjusted relative risk (RR) 0.73, 95% CI 0.67-0.79, I = 31.1%, GRADE low certainty] and cardiovascular events (adjusted RR 0.80, 95% CI 0.69-0.93, I = 47.2%, GRADE low certainty) without serious adverse effect reported. Compared with no vaccination, lower all-cause mortality was observed in those receiving PV combined with IV (Adjusted RR 0.71, 95%CI 0.67-0.75, I = 63.3%), PV alone (Adjusted RR 0.86, 95% CI 0.78-0.94,I = 0%], and IV alone (Adjusted RR 0.76, 95% CI 0.73-0.79, I = 0%]. There was no difference between pneumococcal vaccinated patients vs non-vaccinated patients with respect to pneumonia. Immune response to pneumococcal conjugate vaccine-13 was weaker in polysaccharide pneumococcal vaccine-23-pre-vaccinated compared with vaccine-naive patients.

CONCLUSIONS

The use of pneumococcal vaccine especially combined with influenza vaccination is associated with lower risks of all-cause mortality but may be affected by residual confounding/healthy vaccinee bias.

摘要

背景

透析患者的肺炎球菌疫苗接种率较低,且随着时间推移抗体滴度下降更快,这引发了人们对该人群中肺炎球菌疫苗(PV)有效性的担忧,对此尚未进行系统评价。

方法

我们检索了PubMed、Cochrane图书馆、Embase和三个中文数据库,检索时间从建库至2020年2月29日,以查找评估单独使用PV或联合流感疫苗(IV)对结局(全因死亡率、肺炎、心血管事件、抗体反应和安全性)影响的干预性研究、队列研究和病例对照研究。独立评审人员完成文献筛选、数据提取、风险评估、荟萃分析以及证据质量的GRADE分级。

结果

纳入了五项队列研究和一项半随机对照试验,共394,299例透析患者,证据质量为中到高。与未接种疫苗的个体相比,接种PV的个体全因死亡率风险较低[调整后相对风险(RR)0.73,95%置信区间(CI)0.67 - 0.79,I² = 31.1%,GRADE低确定性],心血管事件风险较低(调整后RR 0.80,95% CI 0.69 - 0.93,I² = 47.2%,GRADE低确定性),且未报告严重不良反应。与未接种疫苗相比,接种PV联合IV的个体全因死亡率较低(调整后RR 0.71,95% CI 0.67 - 0.75,I² = 63.3%),单独接种PV的个体(调整后RR 0.86,95% CI 0.78 - 0.94,I² = 0%),单独接种IV的个体(调整后RR 0.76,95% CI 0.73 - 0.79,I² = 0%)。接种肺炎球菌疫苗的患者与未接种疫苗的患者在肺炎方面无差异。与未接种过疫苗的患者相比,先前接种过23价肺炎球菌多糖疫苗的患者对13价肺炎球菌结合疫苗的免疫反应较弱。

结论

使用肺炎球菌疫苗,尤其是联合流感疫苗,与较低的全因死亡风险相关,但可能受残余混杂因素/健康疫苗接种者偏倚的影响。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验